FDA product code · Cardiovascular

Leadless Cardiac Resynchronization Therapy (Crt)

Name: FDA decisions, review times, recalls and adverse event reports for product code SEG
Creator: 510(k) Report

SEGClass IIIPMA required1 decision since 20250 recalls

1 FDA decision since 2025. No recall names this code.

Leadless Cardiac Resynchronization Therapy (CRT) is intended to deliver CRT using a leadless left ventricular implant

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026 Download the data (CSV)

FIG. A — Illustration, cardiovascular panel

Twenty years of SEG at a glance: how often FDA decides these devices, how long 510(k) reviews take, how often they are recalled, and how many adverse event reports name the code.

FDA decisions per year · SEG

5in 2025

2007high 5 (2025) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · SEG

Too few SEG 510(k)s in any year since 2007 to give a median.

Recalls per year · SEG

No recall names SEG since 2007.

Adverse event reports per year · SEG

43in 2025

2007high 43 (2025) · low 0 (2007)2025

MAUDE reports naming product code SEG, not matched to any one device; reports are not rates.

View these four charts as a table

Year	Decisions	Median 510(k) review, days	MAUDE reports
2007	0	—	0
2008	0	—	0
2009	0	—	0
2010	0	—	0
2011	0	—	0
2012	0	—	0
2013	0	—	0
2014	0	—	0
2015	0	—	0
2016	0	—	0
2017	0	—	0
2018	0	—	0
2019	0	—	0
2020	0	—	0
2021	0	—	0
2022	0	—	0
2023	0	—	0
2024	0	—	0
2025	5	—	43
2026	1	—	—

FIG. 1 — SEG by year, 2007–2026Sources: FDA decision databases, recall and enforcement reports, MAUDE · Data through Oct 25, 2026

Planning a device in SEG? A 510(k) Report ranks candidate predicates in this code by lineage, citations and recall history, with the review-time outlook.

See the 510(k) Report

Leadless Cardiac Resynchronization Therapy (Crt)

What has FDA decided in SEG lately?